St. Jude Beats Estimates, With 'Small Impact' From Boston Sci Absence
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical's better-than-expected first quarter benefited from Boston Scientific's month-long hiatus from the U.S. implantable defibrillator market, but that was not the pivotal factor, according to the company